Summary:
- Lexeo Therapeutics, a biotechnology company, has made progress in discussions with the U.S. Food and Drug Administration (FDA) regarding an accelerated approval pathway for their investigational therapy, LX2006, for the treatment of Friedreich's ataxia cardiomyopathy.
- Friedreich's ataxia is a rare, inherited neurological disorder that affects the nervous system and causes progressive damage to the heart.
- The interim clinical data for LX2006 has shown positive results, indicating the potential for this therapy to address the cardiac complications associated with Friedreich's ataxia.